Search the Blog
Elmiron Lawsuits, Macular Degeneration & How Elmiron May Cause Eye Damage As the number of Elmiron lawsuits continues to grow, many are wondering if this commonly prescribed drug is linked to macular degeneration and other eye problems. A growing number of people are reporting vision issues after taking Elmiron, and there is now evidence that
Medicare fraud is a serious and growing problem that has led to the government losing billions of dollars every year, and whistleblowers are essential in the fight against it. Unbundling fraud is one of the most common types of Medicare fraud and whistleblowers can help to stop it. In this blog post, we’ll look at
The Anti–Kickback Statute and the Stark Law are two important pieces of legislation that are designed to protect patients from fraudulent medical practices and protect taxpayer dollars from being wasted on unnecessary medical care. While these two laws have similar goals, they are actually quite distinct and have different implications for medicare fraud enforcement and the
As the cost of healthcare continues to rise, the government is taking a closer look at pharmaceutical companies that are engaging in Medicare fraud. Pharmaceutical Medicare fraud occurs when a pharmaceutical company or its representatives attempt to defraud the government by overcharging for drugs, upcoding, or submitting false claims. Pharmaceutical companies are particularly vulnerable to misuse of Medicare funds or false claims
Not all patients who are in the ER are admitted, and it is important that those that require in-patient levels of care are treated properly in the ER setting, but recent studies have shown that some for-profit hospital chains enact practices whereby they use quotas or incentives to fraudulently admit patients for inpatient care where
Over the previous months, the United States has intervened in multiple whistleblower cases involving unnecessary medical testing conducted by clinical laboratories and health care providers in several states. These cases demonstrate not only the increased scrutiny with which the DOJ has approached medical testing fraud under the False Claims Act (FCA) but also the vital
The Department of Justice (DOJ) recently released its 2021 False Claims Act (FCA) statistics. A near-record year, the DOJ reported over $5.6 billion recovered in FCA settlements and judgments.
The DOJ’s year-end review presents an excellent opportunity to look back to some of 2021’s most notable FCA cases brought by whistleblowers.
DOJ Announces $5.6 Billion Recovered in False Claims Act Cases Last Year–$1.6 Billion From Whistleblowers
The DOJ recently reported that it obtained more than $5.6 billion in FCA settlements and judgments last year, the second most ever in a year. Over $1.6 billion of this amount stemmed from lawsuits filed by whistleblowers. In total, whistleblowers filed 598 qui tam suits in 2021, and the government paid out over $237 million to whistleblowers.
If the past year is any indication, companies and practitioners involved in medical testing are facing increasing scrutiny under the False Claims Act. We believe that recent trends show just how vital whistleblowers will be to addressing medical testing fraud in the near future.
Private equity firms are facing increasing scrutiny under the False Claims Act (FCA). Recently, the Massachusetts Attorney General announced the largest reported healthcare fraud settlement against a private equity firm, amounting to $25 million. The case was brought under the qui tam provisions of Massachusetts’s FCA. Earlier this year, the DOJ reported a $15.3 million